Hotflash inc

Hotflash inc

Share this post

Hotflash inc
Hotflash inc
It's 'fezo' for short

It's 'fezo' for short

An epic look at Astellas Pharma's big new drug for hot flashes

Hotflash Inc's avatar
Hotflash Inc
Feb 17, 2023
∙ Paid
1

Share this post

Hotflash inc
Hotflash inc
It's 'fezo' for short
7
Share

Screenshot from What’s VMS?

The first non-hormonal drug to treat hot flashes looks like it will hit the US market imminently, with approval of fezolintant anticipated as early as February 22.

If you are wondering why Japan’s Astellas Pharma can put a date on such things, I’ll tell you.

You know what to do.

Keep reading with a 7-day free trial

Subscribe to Hotflash inc to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Hotflash inc
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share